CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA – TRIAL IN PROGRESS Article

Bagley, Stephen, Polley, Mei-Yin, Kotecha, Rupesh et al. (2022). CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA – TRIAL IN PROGRESS . NEURO-ONCOLOGY, 24(Supplement_7), vii64-vii64. 10.1093/neuonc/noac209.253

cited authors

  • Bagley, Stephen; Polley, Mei-Yin; Kotecha, Rupesh; Brem, Steven; Tolakanahalli, Ranjini; Iwamoto, Fabio; Gilbert, Mark; Won, Minhee; Mehta, Minesh

authors

publication date

  • November 14, 2022

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3204 Immunology
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • 6.5 Radiotherapy and other non-invasive therapies
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Neurosciences
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • vii64

end page

  • vii64

volume

  • 24

issue

  • Supplement_7